Literature DB >> 16714763

Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells.

Hiroshi Honda1, Michael J Pazin, Hongxiu Ji, Roman P Wernyj, Patrice J Morin.   

Abstract

Claudins form a large family of tight junction proteins that have essential roles in the control of paracellular ion flux and the maintenance of cell polarity. Many studies have shown that several claudin family members are abnormally expressed in various cancers. In particular, CLDN4 (encoding claudin-4) is overexpressed in ovarian cancer. However, although CLDN4 overexpression is well established, the mechanisms responsible for this abnormal regulation remain unknown. In the present study, we delineate a small region of the CLDN4 promoter critical for its expression. This region contains two Sp1 sites, both of which are required for promoter activity. However, because of the ubiquitous expression of Sp1, these sites, although necessary, are not sufficient to explain the patterns of gene expression of CLDN4 in various ovarian tissues. We show that the CLDN4 promoter is further controlled by epigenetic modifications of the Sp1-containing critical promoter region. Cells that overexpress CLDN4 exhibit low DNA methylation and high histone H3 acetylation of the critical CLDN4 promoter region, and the reverse is observed in cells that do not express CLDN4. Moreover, the CLDN4-negative cells can be induced to express CLDN4 through treatment with demethylating and/or acetylating agents. Because CLDN4 is elevated in a large fraction of ovarian cancer, the mechanism leading to deregulation may represent a general pathway in ovarian tumorigenesis and may lead to novel strategies for therapy and an overall better understanding of the biology of this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714763     DOI: 10.1074/jbc.M603767200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Authors:  Sara Previdi; Anastasia Malek; Veronica Albertini; Cristina Riva; Carlo Capella; Massimo Broggini; Giuseppina M Carbone; Jurgen Rohr; Carlo V Catapano
Journal:  Gynecol Oncol       Date:  2010-05-08       Impact factor: 5.482

2.  MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells.

Authors:  Fengyan Yu; Yu Jiao; Yinghua Zhu; Ying Wang; Jingde Zhu; Xiuying Cui; Yujie Liu; Yinghua He; Eun-Young Park; Hongyu Zhang; Xiaobin Lv; Kelong Ma; Fengxi Su; Jong Hoon Park; Erwei Song
Journal:  J Biol Chem       Date:  2011-11-10       Impact factor: 5.157

Review 3.  Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.

Authors:  Daisuke Kyuno; Hiroshi Yamaguchi; Tatsuya Ito; Tsuyoshi Kono; Yasutoshi Kimura; Masafumi Imamura; Takumi Konno; Koichi Hirata; Norimasa Sawada; Takashi Kojima
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.

Authors:  Babak Litkouhi; Joseph Kwong; Chun-Min Lo; James G Smedley; Bruce A McClane; Margarita Aponte; Zhijian Gao; Jennifer L Sarno; Jennifer Hinners; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

Review 5.  Claudins and the modulation of tight junction permeability.

Authors:  Dorothee Günzel; Alan S L Yu
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

Review 6.  Claudins in cancer: bench to bedside.

Authors:  Makoto Osanai; Akira Takasawa; Masaki Murata; Norimasa Sawada
Journal:  Pflugers Arch       Date:  2016-09-13       Impact factor: 3.657

7.  HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability.

Authors:  M Krishnan; A B Singh; J J Smith; A Sharma; X Chen; S Eschrich; T J Yeatman; R D Beauchamp; P Dhawan
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

8.  Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling.

Authors:  Aya Shinozaki; Tetsuo Ushiku; Teppei Morikawa; Rumi Hino; Takashi Sakatani; Hiroshi Uozaki; Masashi Fukayama
Journal:  J Histochem Cytochem       Date:  2009-04-27       Impact factor: 2.479

9.  Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells.

Authors:  Rachana Agarwal; Yuriko Mori; Yulan Cheng; Zhe Jin; Alexandru V Olaru; James P Hamilton; Stefan David; Florin M Selaru; Jian Yang; John M Abraham; Elizabeth Montgomery; Patrice J Morin; Stephen J Meltzer
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

10.  Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications.

Authors:  Mi Jeong Kwon; Sung-Su Kim; Yoon-La Choi; Hun Soon Jung; Curt Balch; Su-Hyeong Kim; Yong-Sang Song; Victor E Marquez; Kenneth P Nephew; Young Kee Shin
Journal:  Carcinogenesis       Date:  2010-01-06       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.